ERBB2 and neoplasm: However, it is an undeniable fact that 5-year relative survival rate was actually double by modern diagnosis and tumor therapies development in 40 year since several gastric relative targets had been discovered, like Epidermal growth factor receptor (EGFR)5, Human epidermal growth factor receptor 2(HER2)6, Vascular endothelial growth factor(VEGF) family7, Mesenchymal-epithelial transition factor(MET)(8) and Programmed death1(PD1): PDL (PD-ligand) 1/PDL2 pathway8.